In Brief: Boston Scientific/Heart Technology
This article was originally published in The Gray Sheet
Executive Summary
Boston Scientific/Heart Technology: Firms announce Oct. 16 that the Hart-Scott-Rodino waiting period for their proposed $500 mil. stock-swap merger has expired "without any request for more information from the U.S. Department of Justice or the Federal Trade Commission." The companies say that the expiration "eliminates any antitrust obstacle to closing the merger," which was announced in late August. Heart Technology shareholders are expected to vote on the deal in mid-December...